Method and device of treating chronic kidney disease-associated pruritus

Transmucosal nalmefene administration via a mucoadhesive film addresses the lack of effective treatments for chronic kidney disease-associated pruritus by targeting Substance P, offering rapid and effective relief.

US12642796B2Active Publication Date: 2026-06-02AVIOR BIO INC
View PDF 42 Cites 0 Cited by

Patent Information

Authority / Receiving Office
US · United States
Patent Type
Patents(United States)
Current Assignee / Owner
AVIOR BIO INC
Filing Date
2019-10-17
Publication Date
2026-06-02

AI Technical Summary

Technical Problem

There are no approved products in the United States to treat chronic kidney disease-associated pruritus, cholestatic pruritus, or prurigo nodularis, and current treatments like corticosteroids and antihistamines are ineffective for moderate to severe forms, affecting approximately 18% of patients.

Method used

Transmucosal administration of nalmefene or its pharmaceutically acceptable salts, specifically through buccal or sublingual routes, using a single-layer mucoadhesive film with distinct domains for enhanced absorption and permeation, targeting Substance P to mitigate pruritus.

Benefits of technology

The method effectively reduces Substance P levels, providing relief from chronic kidney disease-associated pruritus, cholestatic pruritus, and prurigo nodularis by achieving rapid absorption and therapeutic efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US12642796-D00001
    Figure US12642796-D00001
  • Figure US12642796-D00002
    Figure US12642796-D00002
  • Figure US12642796-D00003
    Figure US12642796-D00003
Patent Text Reader

Abstract

The presently disclosed subject matter is directed to an effective method of treating chronic kidney disease-associated pruritus. Particularly, the method comprises the transmucosal administering of nalmefene to treat chronic kidney disease-associated pruritus, as well as cholestatic pruritus and / or prurigo nodularis. The nalmefene can be configured in a single layer film comprising at least two distinct domains. The film can include a first discrete domain comprising about 50-100 weight percent polymer matrix and the second discrete domain can comprise the nalmefene or pharmaceutically acceptable nalmefene salt.
Need to check novelty before this filing date? Find Prior Art